作者: 巨碩 時(shí)間: 2025-3-21 22:08 作者: finite 時(shí)間: 2025-3-22 03:14
The Clinical Presentation of CLLedominantly a disease of the elderly with a preponderance of male patients. New evidence suggests that there are variations in gender incidence according to the clinical status of patients, with a higher male:female ratio in the groups with worse prognosis..Full blood counts and a physical examinati作者: 儀式 時(shí)間: 2025-3-22 05:08 作者: 鉤針織物 時(shí)間: 2025-3-22 10:59
Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management road acceptance by physicians and investigators caring for patients with CLL. It is not the aim of the iwCLL guidelines to provide treatment recommendations, but definitions for the initial assessment, indication for treatment, and response assessment of CLL. Recent advances including the discovery 作者: gruelling 時(shí)間: 2025-3-22 16:50
Initial Therapy of Chronic Lymphocytic Leukemiaients without very high-risk genomic alterations first-line treatment with chemoimmunotherapy is a well-examined and established standard of care. FCR is the preferred treatment in physically fit patients with mild or no comorbidities. Depending on the burden of comorbidities, less intense chemoimmu作者: gruelling 時(shí)間: 2025-3-22 20:01 作者: Employee 時(shí)間: 2025-3-22 23:24 作者: 上下倒置 時(shí)間: 2025-3-23 03:14
Autoimmune Cytopenia in Chronic Lymphocytic Leukemiauses, patients with CLL presenting cytopenia require a careful evaluation and an individualized management. The association of CLL with cytopenias of immune origin is based on experts’ consensus, and its impact on patients’ outcome remains controversial. It is widely accepted that treatment should b作者: 青少年 時(shí)間: 2025-3-23 08:19
Richter Syndromeare recognized, namely the diffuse large B-cell lymphoma (DLBCL) variant and the rare Hodgkin lymphoma (HL) variant. Histologic documentation is mandatory to diagnose RS. In the presence of clinical features suspicious of RS, diagnosis of transformation and choice of the site of biopsy may take adva作者: 去才蔑視 時(shí)間: 2025-3-23 10:48 作者: 使害怕 時(shí)間: 2025-3-23 17:10 作者: MOTTO 時(shí)間: 2025-3-23 22:01
https://doi.org/10.1007/978-3-658-40787-2ify the presence of prolymphocytes and to consider alternative diagnostic possibilities. In addition, biochemical tests such as beta-2 microglobulin and lactate dehydrogenase are a valuable part of the prognostic evaluation..Patients may need support to deal with the psychological and quality of life issues arising from their disease.作者: arthrodesis 時(shí)間: 2025-3-24 00:07 作者: 無情 時(shí)間: 2025-3-24 03:25 作者: 可耕種 時(shí)間: 2025-3-24 07:47 作者: 提煉 時(shí)間: 2025-3-24 12:52
Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management were recently published and include a revised version of the iwCLL response criteria, an update on the use of the MRD status in the clinical context, and recommendations regarding the assessment and prophylaxis of viral diseases during the management of CLL.作者: insurgent 時(shí)間: 2025-3-24 16:34
Autoimmune Cytopenia in Chronic Lymphocytic Leukemiaibrutinib) might be effective to treat autoimmune cytopenias complicating CLL. Prospective studies are needed to clarify the role of signal inhibitors in the management of autoimmune cytopenias in CLL.作者: acrimony 時(shí)間: 2025-3-24 22:17
2197-9766 adigm in CLL and the emergence of new therapeutic targets.Eq.This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, foll作者: 他一致 時(shí)間: 2025-3-25 02:13 作者: HALO 時(shí)間: 2025-3-25 06:52
Chronic Lymphocytic Leukemia: Who, How, and Where?t when selecting time and type of treatment in CLL patients. We gained further knowledge on the role of B-cell receptor (BcR) signaling and accumulated several hints supporting its key role in CLL development and progression. This led, for the first time in CLL history, to a targeted treatment appro作者: MIRTH 時(shí)間: 2025-3-25 09:56 作者: 火花 時(shí)間: 2025-3-25 11:59
Prognostic Markersr prognosis even with the novel targeted agents and might be considered for experimental approaches or bone marrow transplantation. The possible consequence of the screening results on follow-up, therapy, and quality of life should be discussed with patient and relatives before requesting prognostic作者: Locale 時(shí)間: 2025-3-25 17:33
Initial Therapy of Chronic Lymphocytic Leukemiaed IGHV status the disadvantages of chemoimmunotherapy, such as secondary malignancies or the development of chemo-resistant clones, have to be weighed against its possible benefits, such as the short period of treatment with chemoimmunotherapy compared with the continuous therapy required with nove作者: Prologue 時(shí)間: 2025-3-25 22:39 作者: Eclampsia 時(shí)間: 2025-3-26 03:13 作者: 混合物 時(shí)間: 2025-3-26 05:00 作者: 抵消 時(shí)間: 2025-3-26 09:29
Prolymphocytic Leukaemia of delivering cure. In the last few years many of the molecular mechanisms underlying disease pathogenesis and progression have been revealed and are likely to lead to the development of novel targeted approaches.作者: nugatory 時(shí)間: 2025-3-26 15:29 作者: Lethargic 時(shí)間: 2025-3-26 18:38 作者: exophthalmos 時(shí)間: 2025-3-26 21:16
2197-9766 therapyof T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed...?.978-3-030-11392-6Series ISSN 2197-9766 Series E-ISSN 2197-9774 作者: etidronate 時(shí)間: 2025-3-27 01:57 作者: 混雜人 時(shí)間: 2025-3-27 09:07 作者: Harness 時(shí)間: 2025-3-27 13:05 作者: esthetician 時(shí)間: 2025-3-27 16:18
https://doi.org/10.1007/978-3-658-36376-5ed IGHV status the disadvantages of chemoimmunotherapy, such as secondary malignancies or the development of chemo-resistant clones, have to be weighed against its possible benefits, such as the short period of treatment with chemoimmunotherapy compared with the continuous therapy required with nove作者: 相互影響 時(shí)間: 2025-3-27 18:58
Reflexion (der Gesellschaft) in Twitter,ecommend the use of novel compounds such as ibrutinib, idelalisib, or venetoclax for such patients. However, initial trial results indicate that .mut and del17p continue to be markers of poor prognosis in the context of the novel compounds.作者: 媒介 時(shí)間: 2025-3-27 23:01
https://doi.org/10.1007/978-3-663-02889-5h relapsed/refractory CLL, who have received prior therapy with other alkylating agents or purine analogs. Patients with the presence of del(17p) and/or . mutations should be treated with the BCR signaling inhibitors, ibrutinib or idelalisib. Other patients poorly responding to chemoimmunotherapy in作者: 手術(shù)刀 時(shí)間: 2025-3-28 03:05
Reflexion der Forschungsarbeit,the CLL and the aggressive lymphoma clones. Rituximab-containing polychemotherapy is the back-bone treatment in DLBCL-type RS. Young patients who respond to induction therapy should be offered stem cell transplant to prolong survival. ABVD-related regimen is the preferred regimen for the HL variant 作者: grenade 時(shí)間: 2025-3-28 07:41 作者: 摻假 時(shí)間: 2025-3-28 14:30
Typen der Reflexion metakognitiver Prozesseide, and cyclosporine A remains the current standard of treatment. It is effective in correcting cytopenias in the majority of the patients but usually fails to eradicate the leukemic cell clone. Here, we discuss recent advances regarding the diagnostic workup, molecular pathogenesis, and treatment 作者: Mortal 時(shí)間: 2025-3-28 15:23
https://doi.org/10.1007/978-1-4613-0685-6 remarkable biological and clinical heterogeneity. Key mechanisms underlying CLL onset and progression have been recently dissected. Recent progresses led to the identification of a preneoplastic condition of the disease (i.e., monoclonal B-cell lymphocytosis, MBL) that shed light on very early even作者: 外露 時(shí)間: 2025-3-28 20:12 作者: 諂媚于性 時(shí)間: 2025-3-29 00:14
https://doi.org/10.1007/978-3-658-40787-2edominantly a disease of the elderly with a preponderance of male patients. New evidence suggests that there are variations in gender incidence according to the clinical status of patients, with a higher male:female ratio in the groups with worse prognosis..Full blood counts and a physical examinati作者: glacial 時(shí)間: 2025-3-29 03:11 作者: bromide 時(shí)間: 2025-3-29 09:57
https://doi.org/10.1007/978-3-658-40787-2road acceptance by physicians and investigators caring for patients with CLL. It is not the aim of the iwCLL guidelines to provide treatment recommendations, but definitions for the initial assessment, indication for treatment, and response assessment of CLL. Recent advances including the discovery 作者: 膽小懦夫 時(shí)間: 2025-3-29 15:14 作者: 四海為家的人 時(shí)間: 2025-3-29 17:02
Reflexion (der Gesellschaft) in Twitter, chromosome 17p (del17p) have a worse response to therapy and significantly shorter progression-free survival (PFS) and overall survival (OS). These genetic abnormalities occur in about 10% of untreated and up to 40% of previously treated patients and they define the “ultra-high risk” group among al作者: 生命層 時(shí)間: 2025-3-29 21:02
https://doi.org/10.1007/978-3-663-02889-5 with first-line treatment, the treatment choice of relapsed CLL patients is dependent on several factors, including age, performance status, comorbidities, and duration of response to previous therapy. The outcome of second, and subsequent, lines of therapy is markedly improved by the addition of C作者: 解脫 時(shí)間: 2025-3-30 02:01 作者: offense 時(shí)間: 2025-3-30 05:56
Reflexion der Forschungsarbeit,are recognized, namely the diffuse large B-cell lymphoma (DLBCL) variant and the rare Hodgkin lymphoma (HL) variant. Histologic documentation is mandatory to diagnose RS. In the presence of clinical features suspicious of RS, diagnosis of transformation and choice of the site of biopsy may take adva作者: FLING 時(shí)間: 2025-3-30 11:41 作者: 神圣將軍 時(shí)間: 2025-3-30 13:47 作者: TRACE 時(shí)間: 2025-3-30 17:17
Michael Hallek,Barbara Eichhorst,Daniel CatovskySummarizes current knowledge on all aspects of CLL.Describes the role of different diagnostic procedures.Examines the changing treatment paradigm in CLL and the emergence of new therapeutic targets.Eq作者: 先兆 時(shí)間: 2025-3-30 23:10
Hematologic Malignancieshttp://image.papertrans.cn/c/image/226394.jpg作者: Expand 時(shí)間: 2025-3-31 04:27